收藏切换
Efficacy and safety of durvalumab plus chemotherapy as neoadjuvant regimen in the treatment of locally advanced non-small cell lung cancer patients
收藏切换
Mengmin XU1, Jianye YANG1, Feiyan YANG1, Wenbin HU2, Guobiao YANG1, *
World Clinical Drug | 2022, 43(1) : 45 - 50
Less
收藏切换
World Clinical Drug | 2022, 43(1): 45-50
• Article •
Efficacy and safety of durvalumab plus chemotherapy as neoadjuvant regimen in the treatment of locally advanced non-small cell lung cancer patients
Full
Mengmin XU1, Jianye YANG1, Feiyan YANG1, Wenbin HU2, Guobiao YANG1, *
Affiliations
  • 1.Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Shaoxing University, Shaoxing 312099, Zhejiang Province, China
  • 2.Department of Thoracic Surgery, Affiliated Hospital of Shaoxing University, Shaoxing 312099, Zhejiang Province, China
Published: 2022-01-10 doi: 10.13683/j.wph.2022.01.009
Outline
收藏切换
Objective

To evaluate the efficacy and safety of durvalumab combined with chemotherapy as neoadjuvant therapy for patients with locally advanced non-small cell lung cancer (NSCLC).

Methods

Thirty-eight patients with operable locally advanced NSCLC were enrolled and received two cycles of neoadjuvant therapy with durvalumab combined with paclitaxel/carboplatin, followed by surgical resection. After postoperative recovery, durvalumab alone or in combination with paclitaxel/carboplatin were administered as adjuvant therapy for at least two cycles. Clinical response rate, pathological response rate, disease-free survival (DFS), overall survival (OS) and adverse events were assessed.

Results

After neoadjuvant therapy, the proportions of clinical complete response, partial response, stable disease and disease progression were 0.00%, 65.78%, 31.58% and 2.63%, respectively. The objective response rate (ORR) was 65.78%. Significant pathological response and complete pathological response were 57.89% and 23.68%, respectively. Up to the last follow-up date, three patients (7.89%) relapsed and two patients (5.26%) died. The mean DFS was 15.4 months (95%CI: 14.4-16.3 months), and the mean OS was 15.8 months (95%CI: 15.1 - 16.5 months). The most common adverse events were alopecia (47.37%), nausea and vomiting (42.11%), fatigue (39.47%), anemia (34.21%), neutropenia (28.95%), leukopenia (21.05%) and constipation (21.05%). Most of the adverse events were grade 1 - 2, and only a few were grade 3 - 4.

Conclusion

Durvalumab combined with neoadjuvant chemotherapy can achieve a higher pathological response rate and survival benefit in patients with locally advanced NSCLC, and is well tolerated.

non-small cell lung cancer  /  durvalumab  /  chemotherapy  /  neoadjuvant therapy  /  efficacy and safety
徐萌敏, 杨剑烨, 杨飞燕, 胡汶斌, 杨国彪. 度伐利尤单抗联合化疗作为局部晚期非小细胞肺癌患者新辅助治疗方案的疗效与安全性. 世界临床药物, 2022 , 43 (1) : 45 -50 . DOI: 10.13683/j.wph.2022.01.009
Mengmin XU, Jianye YANG, Feiyan YANG, Wenbin HU, Guobiao YANG. Efficacy and safety of durvalumab plus chemotherapy as neoadjuvant regimen in the treatment of locally advanced non-small cell lung cancer patients[J]. World Clinical Drug, 2022 , 43 (1) : 45 -50 . DOI: 10.13683/j.wph.2022.01.009
Year 2022 volume 43 Issue 1
16
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.01.009
  • Receive Date:2021-10-15
  • Online Date:2026-11-19
  • Published:2022-01-10
Article Data
Affiliations
History
  • Received:2021-10-15
Affiliations
    1.Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Shaoxing University, Shaoxing 312099, Zhejiang Province, China
    2.Department of Thoracic Surgery, Affiliated Hospital of Shaoxing University, Shaoxing 312099, Zhejiang Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.01.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT